A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting

Phase 2

LY4100511A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Sponsor:

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

Code:

NCT06602219

Conditions

Plaque Psoriasis

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

LY4100511

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-20. This information was provided to ClinicalTrials.gov by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company on 2025-05-25.